Detalhe da pesquisa
1.
Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model.
Antimicrob Agents Chemother
; 68(3): e0115723, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38259101
2.
The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease.
Antimicrob Agents Chemother
; 67(11): e0087423, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877693
3.
New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.
Respiration
; 102(2): 83-100, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516792
4.
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics.
Clin Microbiol Infect
; 28(3): 448.e1-448.e7, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34332109
5.
An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.
Clin Pharmacokinet
; 61(6): 907-918, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35377133
6.
The role of amikacin in the treatment of nontuberculous mycobacterial disease.
Expert Opin Pharmacother
; 22(15): 1961-1974, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292097
7.
Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.
Clin Pharmacokinet
; 61(9): 1325-1329, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947361